Josephine B. Walton
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Previous Organizations / Institutes
The organizations / institutes from the scholar's other articles in the past ten years
Research Subjects
Josephine B. Walton has a total of 37 co-authors. Here are the top co-authors by number of shared publications:
- Ana P. Costa Pereira
Department of Biochemistry, University College, Ireland
19 shared publications - Barbara C. Vanderhyden
Cancer Therapeutics Program, Ottawa Hospital Research Institute, Ottawa, Canada
19 shared publications - Carmen Aguirre Hernandez
Ovarian Cancer Action Research Centre, Department of Surgery & Cancer, Imperial College London; London, United Kingdom
19 shared publications - Chloé Woodman
School of Cancer and Pharmaceutical Sciences, King’s College London, London SE1 1UL, UK
19 shared publications - Darren P. Ennis
Department of Surgery and Cancer, Imperial College London, London, UK
19 shared publications - David P. Cook
Cancer Research Program, Ottawa Hospital Research Institute, Ottawa, ON, Canada
19 shared publications
Latest Publications
- Open Access
A molecular glue degrader-antibody conjugate for HER2-targeted cyclin K degradation
Cyclin-dependent kinase 12 (CDK12) is an attractive therapeutic target due to its critical role in transcriptional regulation and DNA damage response and is frequently co-amplified with ERBB2 (HER2) in breast cancer. CDK12 forms an active complex with its obligate partner cyclin K (CCNK), and pharmacological degradation of CCNK has emerged as a promising strategy for disrupting CDK12-dependent transcriptional programs. However, the broad expression and essential functions of the CDK12/CCNK complex may limit the therapeutic window of highly potent molecular glue degraders. Here, we investigate whether antibody-mediated delivery can impart cellular selectivity to a molecular glue degrader through targeting the HER2 receptor. Molecular glues lack the modular architecture of PROTACs, thus linker placement can be the central design problem. We designed SAS1001, a CCNK molecular glue degrader with a solvent-exposed piperazine primed for linker attachment. SAS1001 induced potent and ubiquitin-proteasome system-dependent degradation of CCNK and inhibited proliferation in a range of breast cancer cells. Conjugation to trastuzumab (Tz) generated the HER2-targeted degrader-antibody conjugate Tz-SS2009, which internalized preferentially in HER2-positive cells and produced enhanced CCNK degradation and antiproliferative effects, relative both to HER2-negative cells and to an isotype-matched non-targeting conjugate. Whole proteome analysis further demonstrated CCNK depletion and revealed downstream changes consistent with established roles of the CDK12/CCNK complex in transcriptional regulation. These findings demonstrate that antibody-mediated delivery can redistribute the cellular activity of a potent molecular glue degrader towards antigen-positive cells. In the CR8/DS18 purine series, substitution at a solvent-exposed position preserved CCNK degradation when the degrader was delivered on a full-length IgG. More broadly, this work extends antibody-directed degradation beyond the CRBN-based glues that have dominated the field and illustrates how structural characterization of a glue scaffold can identify a linker attachment point that does not compromise activity.
Open AccessA molecular glue degrader-antibody conjugate for HER2-targeted cyclin K degradation
Cyclin-dependent kinase 12 (CDK12) is an attractive therapeutic target due to its critical role in transcriptional regulation and DNA damage response and is frequently co-amplified with ERBB2 (HER2) in breast cancer. CDK12 forms an active complex with its obligate partner cyclin K (CCNK), and pharmacological degradation of CCNK has emerged as a promising strategy for disrupting CDK12-dependent transcriptional programs. However, the broad expression and essential functions of the CDK12/CCNK complex may limit the therapeutic window of highly potent molecular glue degraders. Here, we investigate whether antibody-mediated delivery can impart cellular selectivity to a molecular glue degrader through targeting the HER2 receptor. Molecular glues lack the modular architecture of PROTACs, thus linker placement can be the central design problem. We designed SAS1001, a CCNK molecular glue degrader with a solvent-exposed piperazine primed for linker attachment. SAS1001 induced potent and ubiquitin-proteasome system-dependent degradation of CCNK and inhibited proliferation in a range of breast cancer cells. Conjugation to trastuzumab (Tz) generated the HER2-targeted degrader-antibody conjugate Tz-SS2009, which internalized preferentially in HER2-positive cells and produced enhanced CCNK degradation and antiproliferative effects, relative both to HER2-negative cells and to an isotype-matched non-targeting conjugate. Whole proteome analysis further demonstrated CCNK depletion and revealed downstream changes consistent with established roles of the CDK12/CCNK complex in transcriptional regulation. These findings demonstrate that antibody-mediated delivery can redistribute the cellular activity of a potent molecular glue degrader towards antigen-positive cells. In the CR8/DS18 purine series, substitution at a solvent-exposed position preserved CCNK degradation when the degrader was delivered on a full-length IgG. More broadly, this work extends antibody-directed degradation beyond the CRBN-based glues that have dominated the field and illustrates how structural characterization of a glue scaffold can identify a linker attachment point that does not compromise activity.
- Open Access
- 17 June 2026
- Published by American Association for Cancer Research (AACR)
Supplementary Figures from PTEN Loss Shapes Macrophage Dynamics in High-Grade Serous Ovarian Carcinoma
- 17 June 2026
- Published by American Association for Cancer Research (AACR)
Open AccessSupplementary Figures from PTEN Loss Shapes Macrophage Dynamics in High-Grade Serous Ovarian Carcinoma
- Open Access
- 17 June 2026
- Published by American Association for Cancer Research (AACR)
Supplementary Figure legends from PTEN Loss Shapes Macrophage Dynamics in High-Grade Serous Ovarian Carcinoma
Legends to supplementary figures
- 17 June 2026
- Published by American Association for Cancer Research (AACR)
Open AccessSupplementary Figure legends from PTEN Loss Shapes Macrophage Dynamics in High-Grade Serous Ovarian Carcinoma
Legends to supplementary figures
- Open Access
- 17 June 2026
- Published by American Association for Cancer Research (AACR)
Table S2 Genes per cluster from PTEN Loss Shapes Macrophage Dynamics in High-Grade Serous Ovarian Carcinoma
Genes upregulated in each mouse macrophage cluster
- 17 June 2026
- Published by American Association for Cancer Research (AACR)
Open AccessTable S2 Genes per cluster from PTEN Loss Shapes Macrophage Dynamics in High-Grade Serous Ovarian Carcinoma
Genes upregulated in each mouse macrophage cluster
- Open Access
- 17 June 2026
- Published by American Association for Cancer Research (AACR)
Table S1 Antibodies from PTEN Loss Shapes Macrophage Dynamics in High-Grade Serous Ovarian Carcinoma
Table of antibodies used in flow cytometry and immunohistochemistry.
- 17 June 2026
- Published by American Association for Cancer Research (AACR)
Open AccessTable S1 Antibodies from PTEN Loss Shapes Macrophage Dynamics in High-Grade Serous Ovarian Carcinoma
Table of antibodies used in flow cytometry and immunohistochemistry.
- Open Access
- 17 June 2026
- Published by American Association for Cancer Research (AACR)
Supplementary Methods from PTEN Loss Shapes Macrophage Dynamics in High-Grade Serous Ovarian Carcinoma
Description of supplementary methods
- 17 June 2026
- Published by American Association for Cancer Research (AACR)
Open AccessSupplementary Methods from PTEN Loss Shapes Macrophage Dynamics in High-Grade Serous Ovarian Carcinoma
Description of supplementary methods
- Open Access
- 17 June 2026
- Published by American Association for Cancer Research (AACR)
Table S3 HMOX1-hi gene expression from PTEN Loss Shapes Macrophage Dynamics in High-Grade Serous Ovarian Carcinoma
Up- and down-regulated differentially expressed genes in HMOX1-hi human macrophages
- 17 June 2026
- Published by American Association for Cancer Research (AACR)
Open AccessTable S3 HMOX1-hi gene expression from PTEN Loss Shapes Macrophage Dynamics in High-Grade Serous Ovarian Carcinoma
Up- and down-regulated differentially expressed genes in HMOX1-hi human macrophages
- Open Access
- 18 November 2024
- Published by American Association for Cancer Research (AACR)
Table S1 Antibodies from PTEN Loss Shapes Macrophage Dynamics in High-Grade Serous Ovarian Carcinoma
Table of antibodies used in flow cytometry and immunohistochemistry.
- 18 November 2024
- Published by American Association for Cancer Research (AACR)
Open AccessTable S1 Antibodies from PTEN Loss Shapes Macrophage Dynamics in High-Grade Serous Ovarian Carcinoma
Table of antibodies used in flow cytometry and immunohistochemistry.
- Open Access
- 18 November 2024
- Published by American Association for Cancer Research (AACR)
Supplementary Figures from PTEN Loss Shapes Macrophage Dynamics in High-Grade Serous Ovarian Carcinoma
Supplementary Figures from PTEN Loss Shapes Macrophage Dynamics in High-Grade Serous Ovarian Carcinoma
- 18 November 2024
- Published by American Association for Cancer Research (AACR)
Open AccessSupplementary Figures from PTEN Loss Shapes Macrophage Dynamics in High-Grade Serous Ovarian Carcinoma
Supplementary Figures from PTEN Loss Shapes Macrophage Dynamics in High-Grade Serous Ovarian Carcinoma
- Open Access
- 18 November 2024
- Published by American Association for Cancer Research (AACR)
Supplementary Methods from PTEN Loss Shapes Macrophage Dynamics in High-Grade Serous Ovarian Carcinoma
Description of supplementary methods
- 18 November 2024
- Published by American Association for Cancer Research (AACR)
Open AccessSupplementary Methods from PTEN Loss Shapes Macrophage Dynamics in High-Grade Serous Ovarian Carcinoma
Description of supplementary methods